<DOC>
	<DOCNO>NCT01181895</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety vilanterol inhalation powder administer daily even adolescent adult subject 12 year age old persistent asthma 12-week treatment period .</brief_summary>
	<brief_title>Study B2C112060 : A Study Efficacy Safety Vilanterol Inhalation Powder Adults Adolescents With Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Outpatient least 12 year age Both gender ; female childbearing potential must willing use birth control method Clinical diagnosis asthma â‰¥12 week Best prebronchodilator FEV1 40 % 90 % predicted Reversibility FEV1 least 12 % 200mls Current asthma therapy include inhale corticosteroid least 12 week prior 1st visit Ability use replace current shortacting rescue treatment albuterol ability withhold albuterol use least 6 hour prior study visit History lifethreatening asthma Respiratory infection within last 4 week lead change asthma management Asthma exacerbation within last 3 month Concurrent respiratory disease disease would confound study participation affect subject safety Allergies study drug , study drug ' excipients , medication relate study drug Taking another investigational medication medication prohibit use study . Previous participation vilanterol ( GW642444 ) study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>asthma</keyword>
</DOC>